Six innovative drugs developed by companies in SIP’s BioBAY have been newly included in the national medical insurance drug list. This will substantially reduce treatment costs and accelerate the delivery of cutting-edge therapies to patients in critical need.

Among these drugs are CStone Pharmaceuticals’ GAVRETO? (pralsetinib) capsule, a potent, selective oral Rearranged during Transfection (RET) inhibitor, and Retsevmo? (selpercatinib), a selective and potent RET kinase inhibitor developed by Eli Lilly and Company and solely commercialized in Chinese Mainland by Innovent Biologics.

Innovent Biologics’s SYCUME? (Teprotumumab N01 Injection), a recombinant monoclonal antibody that specifically targets the insulin-like growth factor 1 receptor (IGF-1R), is also on the list as a drug for eye diseases.

Suzhou Suncadia Biopharmaceuticals has three new drugs added to the list: the Vunakizumab Injection for the treatment of adult patients with moderate-to-severe plaque psoriasis through systematic treatment or phototherapy and also those with active ankylosing spondylitis (AS) who respond inadequately to conventional therapies; Trastuzumab Rezetecan for Injection for the treatment of adults with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have human epidermal growth factor receptor 2 (HER2) [ERBB2]-activating mutations and have received at least one previous systemic treatment; and Recaticimab for Injection, which is used for the treatment of hypercholesteremia and mixed dyslipidemia.

December 11, 2025